All the Active Ingredient Drugs
Selective IP Receptor Agonist. Selexipag 200, 400, 600, 800, 1000, 1200, 1400, 1600 mcg. TABS.: 60×200, 400, 600, 800, 1000, 1200, 1400, 1600 mcg
Individ. dose titrat. : Each patient should be up titrated to the highest individ. tolerated dose, which can range from 200 mcg given twice dly. to 1,600 mcg given twice dly. (individ. maint. dose). The recom. init. dose 200mcg given twice dly., approx. 12 hrs. apart. The dose is incr. in increm. of 200 mcg given twice dly., usually at wkly. intervals. In pts. in whom up titration was limited by reasons other than adr. reflect. the mode of action of Selexipag, a 2nd attempt to cont. up titrat. to the highest individ. tolerated dose up to a max. dose of 1,600 msg twice dly. may be considered. Individual. maint. dose. The highest tolerated dose reached during dose titrat. should be maint. . If the therapy over time is less tolerated at a given dose, symptomatic tmt. and/or a dose reduction to the next lower dose should be considered.
Long-term tmt. of pulmon.art. hypertens. (PAH) in adult pts. with WHO funct. class (FC) II–III, either as combin. ther. in pts. insuffic. control. with an endothelin receptor antag. (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhib., or as monother. in pts. who are not candidates for these therapies. Efficacy has been shown in a PAH population includ. idiopathic and heritable PAH, PAH assoc. with connective tissue disor., and PAH assoc. with corrected simple congen. heart dis.
C/I: Hypersens.. Severe coron. heart dis.or unstable angina. MI within the last 6 mnths. Decompens. cardiac fail.if not under close med. supervis. Severe arrhythmias. Cerebrovasc. events (e.g., TIA, stroke) within the last 3 mnths. Congen. or acquired valvular defects with clinical. relevant MI disord. not related to pulmon. hypertens.